Study to Investigate the Performance of Cervical Arthroplasty for the Treatment of Cervical Degenerative Disc Disease

Phase 4TerminatedNCT00700739

DePuy International60 enrolled

Overview

The purpose of the study is to evaluate the performance of the Discover cervical Artificial disc in the treatment of degenerative disc disease in one level of the cervical spine.

The protocol underwent 3 amendments, the last of which (02APR2009) changed the study design from a randomized to a non-randomized and non-comparative clinical trial. All of the subjects were enrolled under the randomized design with the exception of the last subject. This study is not applicable per FDAA Title VIII, Section 801 due to the final trial design. However, results are submitted to clinicaltrials.gov due to the majority of study data being collected under a randomized (FDAA Title VIII, Section 801 applicable) trial design

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Cervical Degenerative Disc Disease

Interventions

DISCOVER™ Artificial Cervical DiscDEVICE

DISCOVER™ Artificial Cervical Disc

ACDFDEVICE

Cervical CFRP I/F CAGE® and SLIM LOC(R) Anterior Cervical Plate System with allograft

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female subjects, aged between 18 and 65 years inclusive. * Subjects who are able to give voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained. * Subjects who, in the opinion of the Clinical Investigator, are able to understand this clinical investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups. * Objective evidence of cervical disc disease in one vertebral level between C3-C7 defined as one or more of the following: * Shoulder and/or arm pain in a radicular distribution resulting from herniated disc or bony osteophytes (Consistent w diagnostic imaging including Axial CT, CT Myelogram, MRI and/or plain films) * Subjects with myeloradiculopathy resulting from mild spinal cord compression and nerve root impingement * Unresponsive to documented non-surgical management for ≥ 6 weeks and/or presents with progressive symptoms of nerve root or spinal cord compression in the face of continued non-surgical management (e.g., physical therapy, medication therapy, corticosteroid injections, etc.) * Minimum Neck Disability Index score of ≥30 % (15/50 points) Exclusion Criteria: * Subjects who, in the opinion of the Clinical Investigator, have an existing condition that would compromise their participation and follow-up in this clinical investigation. * Subjects who are pregnant, lactating or wishes to become pregnant within the duration of the study. * Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes. * Subjects who have participated in a clinical investigation with an investigational product in the last 30 days. * Subjects who are currently involved in any injury litigation claims. * Subjects with significant degeneration at more than one cervical level (e.g. DISH, ankylosing spondylitis, congenital abnormality, rheumatoid arthritis) * Subjects who have had any prior surgery at the level to be treated (subjects with a prior Laminotomy at the level to be treated may be included in the study) * Subjects who have marked cervical instability on lateral or flexion/extension x-rays defined as translation ≥3mm and/or ≥11 degrees of rotational difference to either adjacent level * Subjects who have presence of systemic infection or infection at the site of surgery * Subjects who have been diagnosed with malignancy * Subjects who have been diagnosed with a condition or require postoperative medication(s) that may interfere with bony/soft tissue healing * Subjects who have been diagnosed with Osteoporosis, Osteopenia, other metabolic bone disease or endocrine disorder known to affect osteogenesis. * Subjects with pre-existing neurological abnormalities other than deficits produced from the spinal lesion (e.g., MS, Parkinson's, CVA, diabetic neuropathy, peripheral neuropathy). * Subjects with morbid obesity defined as a BMI of ≥40, or more than 100 lbs (45.4kg) over ideal weight. * Subjects with any known allergy to titanium metal, polyethylene, metal alloy or carbon fibre reinforced polymer * Subjects who have had prior fusion surgery at any level(s) (C1-T1) * Subjects with kyphosis \>-15 degrees evaluated using the Cobb angle measurement * Subjects with Significant cervical degenerative disease characterized by bridging anterior osteophytes, significant loss of disc space height (3mm or less), sclerotic facets, large posterior osteophytes, autofusion of other cervical levels, and degenerative retrolisthesis. Spinal diseases such as DISH, ankylosing spondylitis, congenital abnormality, and rheumatoid arthritis, should also be excluded * Subjects undergoing treatment with a bone growth stimulator, which cannot be discontinued prior to enrollment in the study. * Significant kyphotic deformity or significant reversal of lordosis.

Locations (8)

Westmead Private Hospital

Sydney, New South Wales, Australia

Calvary Hospital

Tasmania, Australia

Klinikum Neustadt

Neustadt, Holstein, Germany

Divisione di Neurochirurgia

Rome, Italy

Outcomes

Primary Outcomes

Overall Patient Success

Overall success was a composite endpoint determined by the following clinical outcome measures: 1. Neck Disability Index ≥ 15-point improvement from baseline to 12 months post-operative, 2. No new clinically significant permanent abnormalities in neurological function (i.e. motor strength, nerve root tension signs, sensory and reflex signs) from baseline to 12 months post-operative, 3. No subsequent secondary surgical interventions (SSI) at the index level, and 4. No device-related serious events (dSAE) from intra-operative through 12-months post-operative. Please note that these time periods were intended to be from baseline to 24 months post-operative, but since the study was terminated early the 12 month time periods were utilized.

Time frame: 12 months

Secondary Outcomes

Change in Visual Analogue Scale (VAS) Neck Pain From Pre-treatment to 12 Months

The visual analogue scale (VAS) pain score asks the subject to place a vertical mark on a horizontal line (that is approximately 10 cm long) with 'No Pain' (score of 0 = 0 cm) listed on the left and 'Very severe pain' (score of 100 = 10 cm) labeled on the right. The subject is instructed to indicate the amount of pain they feel in their neck.

Time frame: 12 months

Change in Visual Analogue Scale (VAS) Left Arm Pain From Pre-treatment to 12 Months.

Time frame: 12 Months

Change in Visual Analogue Scale (VAS) Right Arm Pain From Pre-treatment to 12 Months.

The visual analogue scale (VAS) pain score asks the subject to place a vertical mark on a horizontal line (that is approximately 10 cm long) with 'No Pain' (score of 0= 0 cm) listed on the left and 'Very severe pain' (score of 100= 10 cm) labeled on the right. The subject is instructed to indicate the amount of pain they feel in their right arm.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.